Member Info for The_Paladin

Didn’t Alfred the butler (Michael Caine) say something similar to young Bruce Wayne in Batman Begins ?

A very good point concerning Long Covid symptoms was raised by Waiteoxford earlier today. The link below is to a brief science.org article, which takes the arguments a step further.

“ We're surely going to end up classifying this with a whole list of other post-infection syndromes …..
….. it has always appeared to me to be a trackless swamp. The arguing about these has been literally going on for decades,“

Apparently the kind of attention currently given to Long Covid has been paid to similar persistent post infection symptoms of other diseases for many years. Has Long Covid been brought to the fore because of the large number of sufferers, and the possible economic consequences of their debilitating symptoms?

https://www.science.org/content/blog-post/long-covid-long-other-things

I made a similar error on this forum when discussing the Synairgen team, who were present at another conference. All the co-authors listed together with Dr. Monk are unlikely to have attended? It would have resulted in a lot of unjustified expense. However, unless we are informed by the company there is no way of ascertaining who was present?

My main interest lies with (i) Whether Dr. Monk offered any additional LC data, and analysis in his presentation? (ii) Have we attracted any interest from potential BP partners? If there are discussions underway with potential partners, they may go on for some time?

I agree that SNG001’s potential to suppress LC symptoms following early treatment of patients with severe Covid symptoms is worthy of additional investigation. As stated previously, my view is that it should be investigated as part of a P3 Sprinter-style Covid trial.

In the long term, Synairgen must be looking at deploying SNG001 as a broad- spectrum anti-viral treatment? This is what their recent statement suggests. All this will take time and huge resources.

The company’s first priority is to secure that elusive trial. When that happens, it will hopefully shake off the irritating little dabblers who have been playing havoc with our share price this week?

GLA

Thank you Mani.

It looks like a repeat of the previous LC data RNS, with refinement? Should anything new have emerged, it would have been RNSd before now?

Patience remains the key with this investment. One of Warren Buffet’s quotes maintains that one should not invest in shares unless one is prepared to hold onto them for a very long time. The investment case here remains strong, although it is going to take longer than I had originally anticipated to achieve my goal. (Originally 300p per share; currently 150p per share after doubling down, although some pragmatism may be effected prior to the latter price target, if achieved?).

I wasn’t invested at the time, but remember reading about the swift rise in share price on another forum. What caused such an abrupt rise at the time?

Although the share price has declined to low levels over the last two years, the company seems to be in good shape for future developments. I believe that patience is the key. It will need to be in my case as I am currently underwater with this investment.

My mistake ProfessorSPD. I read your number, and linked it to the thread title, and not to gunto2022’s comment as I should have done. It happens, especially so with an early start. ATB.

ProfessorSPD.
An audience of 64 at Dr Monk’s presentation last Friday would have been encouraging for him; also for Synairgen, and for all LTIs. Where did you get that number from? When I checked the conference website last Friday evening, there were 31 declared attendees. The representatives from some major pharmaceutical companies listed by Wigster78 yesterday offers us encouragement. I am expecting feedback from the company this week - probably the presentation slides, but who knows what might have happened since then?

I was surprised to read so many comments from sensible LTIs concerning the posts from obvious disrupters to this forum? Why not use the filter facility? It is what it is there for.

Not only was Docdaneeka referring to JoeyD, but he ended his comment with: “You’re anti everything - vaxes - mabs - except our inadequately trialed drug”, as any Synairgen investor would do.

Good find Jakman59, although I agree that this abstract should be taken with a pinch of salt.

IMO It is too early for Pres. Biden, Dr. Tedros, and others to signal that we are in a post pandemic era. Apparently, there is a challenging Winter ahead in the UK and elsewhere. We shall just have to see what emerges?

When I read the abstract, I agreed with Fruitsnveg that it is an amalgam, mostly of the Feb 21 RNS, and the more recent one bringing the post sprinter LC data to the fore. Dr. Monk will have added more information to that initial RNS in his presentation. Synairgen will give us the full picture early next week.

I was encouraged to see BP representatives among the declared 31 attendees at Dr. Monk’s short presentation. There will no doubt have been opportunities for Dr. Monk to network if further clarification was necessary?

I see last night’s event as an important part of a much bigger picture. The company has done well in picking themselves up, and unearthing solid and positive data over the last eight months. Synairgen now has a good chance of securing a Covid trial, by whatever route, with LC ramifications included. Fortunately, we have other opportunities, which could be pursued sequentially following a successful Covid trial. First, let’s see what next week brings?

There are nine consecutive green rectangles on my screen. Presumably from the same individual? If so, s/he has definitely lost the plot.

Have a good weekend everybody.

Will Synairgen add today’s presentation slides to their website following the session, or will they leave it until next week?

It is of no concern to me when an RNS is released. The important factor is its content.

A notification with additional scientific content would no doubt be useful for the future. It would add to the current growing data and results portfolio.

An announcement of a trial invitation, a JV, or an acquisition of the company at a fair price would be far more interesting. Ultimately, this is what Synairgen’s good work over the last seven months is leading to.

We make too much of Synairgen’s every action on this forum. The ID Week 2022 is massive. Dr. Monk’s presentation is one among a huge number of presentations, and group discussions of a similar quality. I was impressed by the size and scope of the conference when surveying through the programme yesterday evening.

The important fact for me is that Synairgen have staged a good recovery since last February. They should have nailed the Sprinter trial, but mistakes were made. We have all been there, I’m sure. The important factor is that the company has picked itself up, and gone on with the business of moving towards the commercialisation of a multi-viral treatment. This was always going to take time, and good progress has been made to date.

Our data suggests that we will achieve a trial invitation? The situation may be under discussion already? Synairgen will let investors know as soon as as they have secured an agreement.

This is proving to be a longer term investment than originally envisaged. We will get there eventually.

https://www.eventscribe.net/2022/IDWeek/

Probably the silliest comment on this forum today! I may be morphing into a conspiracy theorist?

However, I have just noticed that Synairgen have changed the format of their LinkedIn message regarding Friday’s LC results presentation at the IDWeek 2022 conference. The picture of Dr. Monk has also been enlarged, with just the event and date on its right.

A similar change has been effected on the corresponding tweet.

The previous version gave the necessary information. Why did they bother to change the format just a few days before the event?

The revised LinkedIn format:

“For #Media and #Analysts

Are you onsite at #IDWeek2022? Meet with us by contacting us at info@synairgen.com

Our CSO Dr Phillip Monk will be presenting the 60- and 90-day #LongCOVID data from our Phase 3 SPRINTER trial in hospitalized #COVID19 patients at ID Week on Friday, October 21 at 2:35pm ET in Washington DC.”

The revised tweet:

#SNG pic.twitter.com/AySsJNVWcu

This afternoon , I received the same standard reply, from Brooke Clarke, regarding my enquiry last Monday. This was concerned with the potential of SNG001 for a place on a trial for a Covid treatment for immunosuppressed patients.

I take the fact that at least three investors have received this reply in response to enquiries about potential trials as a positive. While wearing my best deer stalker hat, I now believe that there is a game afoot, and we will be hearing from the company in the not too distant future.

“We aren’t disclosing the specifics of our discussions and applications with specific trials but as soon as we have a concrete trial or trials agreed we will make an announcement.“

GLA.

In mid February, Synairgen were about to bring Ray Jordan on board. Sadly a few days later, we no longer had any use for his extensive skills set.

At the present, time when we are seeking a trial opportunity, it might be a good idea to bring someone like Ray Jordan inside the tent? I suspect that Dr. Flic Gabbay was recruited for similar reasons?

https://instituteforpr.org/ipr-bio/raymond-jordan/

Synairgen needs to follow up its potential as a preventative treatment to minimise the risk of LC in Covid patients asap. There is a multiplicity of other solutions being looked at mostly from the treatment perspective. The link below gives a treatment currently under investigation.

https://www.reuters.com/business/healthcare-pharmaceuticals/addiction-drug-shows-promise-lifting-long-covid-brain-fog-fatigue-2022-10-18/

Friday’s IDweek 2022 presentation is a valuable opportunity to attract further attention to our LC prevention solution. Roll the dice Dr. Monk. Go for it!

I agree with Docdaneeka that a LC trial by itself would be a wasted opportunity. To repeat part of my post yesterday, a successful outcome to a well designed Sprinter equivalent trial, with an inbuilt detailed LC trial follow-on, could be the making of Synairgen? It is time for the company to use the high quality data that has been obtained since February as leverage to obtain a JV trial with a BP company.

RM stated that the quality senior leadership appointees over the last year or so were being retained to assist with trial negotiations. It is also time for our team of industry experts to step up and get an SNG001 trial deal done. I would be the first to applaud their success should this prove to be the case.

Dr Phillip Monk will be presenting the full analysis of 60- and 90-day LongCOVID data from our Phase 3 SPRINTER trial in hospitalised COVID19 patients at IDWeek on Friday, 21 October in Washington DC. 

Two aspects of this have piqued my interest.

* the full analysis of 60- and 90-day LongCOVID data from our Phase 3 SPRINTER trial in hospitalised COVID19 patients .

This implies that there is more to follow the data that has already been released. Expert opinions lead us to believe in a reasonable possibility of an extended LC trial. My understanding is that it would be an extension of the Sprinter trial with careful qualitative measurement of LC symptoms at fixed time periods following the treatment? Patients could be categorised in sub-groups, with blood samples taken to enhance the subsequent analysis?

* Planning to attend? We’d love to hear from you! Contact us to set up a meeting: info@synairgen.com

Synairgen is open to discuss their results with parties looking for further clarification. Should the data and subsequent discussion generate sufficient interest the door could well open for a JV with a BP company to move SNG001 towards an efficiently conducted trial?

I am happy to see increased investor interest this week. I am hoping that the week will end well. It will be down to Dr. Monk to roll the dice, and use the multiple data sets at his disposal to sell SNG001 to potential JV partners. It may well be the case that this process is underway? The big reveal will hopefully happen sooner or later.

On that subject, we no longer seem to have any news “from the bridge”? Did the regular highly optimistic messages from the Reddit board experts contribute to our misplaced enthusiasm at the time?

That being said, every investor is responsible for his/her investment portfolio. I have learned to be more cautious in future. If the opportunity arises, as previously, to take my original investment off the table, and keep a holding of free shares, I will take it next time around.

Agreed Mani.

My broker will buy all my shares in a single purchase within the current low trading range. Similarly my broker will sell me 50,000 shares in a single transaction. I haven’t attempted to dummy purchase any more than this , but it may be possible as in the case of the dummy sell?

I have been going through this kind of activity on a regular basis, and the ease with which Synairgen shares may be traded has persisted in recent weeks.

I remain optimistic, but would wish to see the company’s shares trading at a considerably higher level than at present before considering what lies ahead?

ATB and GLA